Keeping Track: Breakthroughs Of Summer Break Ground In Psychiatry, Cancer (Especially Nasopharygeal Cancer) And Vaccines
Executive Summary
US FDA’s marquee expedited review program added 15 new breakthrough therapy designations between June and August.
You may also be interested in...
Rx For Immuno-Oncology Excess? Top US FDA Cancer Officials Take On Development ‘Wild West’
Rapid, uncoordinated growth has turned the PD-1/L1 inhibitor pipeline into a global stampede, FDA’s Pazdur and Beaver say. Solutions like a unified submission pathway and coordinated trial design pose challenges requiring international cooperation among governments and industry alike.
US FDA’s Foreign Data Policy Faces Its Greatest Test From Chinese PD-1/L1 Inhibitors
The swift rise of China’s oncology R&D has put at least four novel applications before FDA with pivotal data generated only in China.
Eisai Bets On Accelerated Approval For Biogen-Partnered Lecanemab
Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results.